link.springer.com
Differentiating IL-23 Inhibitors in Crohn's Disease | Drugs
IL‑23 inhibitors are an important and growing class of drugs for Crohn’s disease. Comparing them helps patients and clinicians understand differences in trial results, approvals, and possible treatment choices.
Patients on or considering biologic therapy (especially IL‑23/IL‑12/23 agents), IBD clinicians, and researchers studying biologic treatments or biomarkers.
What To Know
This review article compares IL‑23–targeting therapies for Crohn’s disease and discusses related clinical evidence and drug differences. It names specific IL‑23 inhibitors (risankizumab, guselkumab, mirikizumab) and the IL‑12/23 inhibitor ustekinumab, and cites phase 3 trials and efficacy/safety literature.
The piece appears to focus on how these agents differ and may include discussion of biomarkers and trial outcomes. The article summarizes current IL‑23 and IL‑12/23 biologics used or studied in Crohn’s disease, highlighting individual drugs rather than broad class statements. It references phase 3 trials and comparative data for several agents.
It may discuss ways clinicians assess response or choose between these drugs, including trial endpoints or biomarkers. If you use or are considering a biologic, this review could help you understand how different IL‑23–targeted options have been studied and how they compare in clinical trials.
It does not provide treatment advice or specific recommendations for individual care; discuss any medication changes with your clinician. For clinicians and researchers, the article compiles trial references and comparative information about IL‑23 vs IL‑12/23 inhibition in Crohn’s disease.
This is a scholarly review in a pharmacology journal that cites phase 3 trials and other studies. Reviews summarize existing evidence but do not replace individualized medical advice. The article likely focuses on trial data and drug characteristics rather than new primary trial results.
